CEL-SCI Announces Closing Of Public Offering For Gross Proceeds Of $10 Million

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 7,128,229 shares of common stock and warrants to purchase an aggregate of 1,782,057 shares of common stock. The units were sold at a price of $1.40 per unit and resulted in aggregate gross proceeds of approximately $10 million, prior to deducting underwriting commissions and offering expenses. The common stock and warrants will separate immediately. The warrants are immediately exercisable, expire on October 17, 2014, and have an exercise price of $1.58 per share.

Help employers find you! Check out all the jobs and post your resume.

Back to news